Device-specific vigilance guidance: breast implants
Published 15 January 2025
Introduction Â
This document provides guidance for manufacturers of breast implants. It outlines specific scenarios to consider when determining if an incident is reportable. You should read this document in conjunction with guidance on post-market surveillance. Â
The aim of this guidance is to complement the requirements of . You should read it in conjunction with this regulation. Device-specific guidance does not replace or extend these requirements. Â
What to reportÂ
The following examples indicate how to report device performance problems associated with breast implants that caused or contributed to an incident. The examples are for illustrative purposes only and do not constitute an exhaustive list. If an incident appears to meet criteria contained in more than one category, ensure it is included in submissions under each reporting format, even if this results in duplication of reporting for that incident.Â
1. Report as individual incidents (in line with reporting timescales)Â
Clinical / symptomatic (IMDRF ANNEX E codes)Â Â
The IMDRF annex codes associated with each text description are included as guides in the following:Â
-
breast cancer E180101 / E1403Â
-
suspected and confirmed cases of BIA-ALCL E180102Â
-
lymphoma E180104Â
-
double capsule E2341Â
-
siliconoma E2317Â
-
recurrent seroma/fluid collections E0307Â
-
unexpected breast swelling (seroma / fluid collections with no clinical history for trauma or infections) E0307Â
-
unexpected breast inflammatory reaction (breast inflammatory reaction and/or lymphadenopathy with no clinical history for trauma or infections) E0308Â
-
unexpected breast infection (breast Infections with no clinical history for previous systemic infections) E1906Â
-
systemic adverse reaction, hypersensitivity, allergic reaction E0402Â
-
autoimmune disease or syndrome induced by adjuvants (ASIA) E0401Â
Device (IMDRF Annex E codes)Â
The IMDRF annex codes associated with each text description are included as guides in the following:Â
-
silicone migration A010402Â
-
valve failure (during or after implantation) A041001 / A05 / A1501 / A1406Â Â
2. Incidents that may be included in periodic summary reports (PSR) on agreementÂ
If you cannot use PSR, then report these events individually.Â
Clinical / symptomatic (IMDRF ANNEX E codes)Â Â
The IMDRF annex codes associated with each text description are included as guides in the following:Â
- capsular contracture causing breast deformity and/or pain and/or hard breast E2303 / E1402 / E2332 / E2308 - report every 3 months or as agreedÂ
Device (IMDRF Annex E codes)Â
The IMDRF annex codes associated with each text description are included as guides in the following:Â
-
implant ruptures (independently by the implantation time) A0412 / A040101/ A0413 / A0414 / A140102 - report every 3 months or as agreedÂ
-
post FSCA/FSN incidents provided they have been previously agreed with the MHRA -Â Â reporting frequency as agreedÂ
3. Report at the time of a significant increase in the frequency or severity of incidentsÂ
Clinical/symptomatic (IMDRF Annex E codes)Â
The IMDRF annex codes associated with each text description are included as guides in the following:Â
-
extrusion of the implant.Â
-
wrinkling of the breast E1723Â
-
loss of nipple sensitivity E1409Â
-
breast swelling/ infection/ inflammatory reaction and/or lymphadenopathy with positive clinical history for previous systemic infections or trauma E2338Â
-
calcium deposits E230901Â
Device (IMDRF Annex E codes)Â
The IMDRF annex codes associated with each text description are included as guides in the following:Â
-
rotation /folding/ displacement of the implant A010402 / A0512Â
-
extrusion of the implant A0411 / A050401